Novel Drug Delivery Systems(NDDS):

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

New Molecular Entity (NME) Platforms:

NCE platform (new chemical entity based on innovative targets and PROTACs); NTE platform (new therapeutic entity based on improving physicochemical properties); PDC platform (peptide drug conjugate); key technical processes such as target discovery, drug design and synthesis, screening and evaluation have been established, with more than 10 projects launched to find new drug candidates;

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

BA-huMab® platform: Directly generate human antibodies without need for humanization, which significantly accelerates antibody discovery process and decreases immunogenicity risk; Elicit an immune response quickly and produce a high antibody titer after immunization; Phage display technology platform: Efficient animal immunity technology; Mature phage library construction technology; High-throughput and diverse phage based panning strategies; Diverse evaluation capabilities for antibodies or antibody fragments;

Bispecific T-cell Engager Technology Platform:

Demonstrate high avidity with tumor target antigen by bivalent binding to achieve better drug efficacy; Demonstrate low affinity with T cells by monovalent binding to lower toxicity; Reduce CD3 antibody binding affinity, to significantly reduce the risk of CRS;

ADC Technology Platform:

Design, synthesize and screen the potential ADC linker-payload; Identification of potential internalized antibodies; Diverse antibody conjugation technologies; Evaluation of ADC in vitro and in vivo; Process development and quality analysis for ADC products;

Nucleic Acid Therapy and Gene Therapy:

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

CAR-T Cell Immunotherapy:

Developing next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;